NCT06346067 2026-02-27
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Erasca, Inc.
Phase 3 Active not recruiting
Erasca, Inc.
Merck Sharp & Dohme LLC
AstraZeneca
Takeda
Philogen S.p.A.